Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001104659-17-025040
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-04-21 06:16:46
Reporting Period:
2017-04-19
Filing Date:
2017-04-21
Filing Date Changed:
2017-04-21
Accepted Time:
2017-04-21 07:16:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
850261 Sorrento Therapeutics Inc. SRNE Services-Commercial Physical & Biological Research (8731) 330344842
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1609313 Ally Bridge Group Capital Partners Ii, L.p. Unit 3002-3004, 30Th Floor,
Gloucester Tower, The Landmark, Central
Hong Kong K3 00000
No No Yes No
1667354 Ltd Fund Master Healthcare Lb Bridge Ally Unit 3002-3004, 30Th Floor,
Gloucester Tower, The Landmark, Central
Hong Kong K3 00000
No No Yes No
1668027 Ltd Management Abg Unit 3002-3004, 30Th Floor,
Gloucester Tower, The Landmark, Central
Hong Kong K3 00000
No No Yes No
1668028 Ltd Management Lb Bridge Ally Unit 3002-3004, 30Th Floor,
Gloucester Tower, The Landmark, Central
Hong Kong K3 00000
No No Yes No
1668029 Fan Yu Unit 3002-3004, 30Th Floor,
Gloucester Tower, The Landmark, Central
Hong Kong K3 00000
No No Yes No
1668219 Bin Li Unit 3002-3004, 30Th Floor,
Gloucester Tower, The Landmark, Central
Hong Kong K3 00000
No No Yes No
1674513 Ally Bridge Group Innovation Capital Partners Iii, L.p. Unit 3002-3004, 30Th Floor,
Gloucester Tower, The Landmark, Central
Hong Kong K3 00000
No No Yes No
1676083 Ltd Srne Abg Unit 3002-3004, 30Th Floor,
Gloucester Tower, The Landmark, Central
Hong Kong K3 00000
No No Yes No
1676141 Ltd Ii-So Abg Unit 3002-3004, 30Th Floor,
Gloucester Tower, The Landmark, Central
Hong Kong K3 00000
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-04-19 550,000 $2.00 1,991,441 No 4 P Indirect Through Ally Bridge LB Healthcare Master Fund Limited See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect Through Ally Bridge LB Healthcare Master Fund Limited See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,397,853 Indirect Through ABG II-SO Limited See footnote
Common Stock 3,243,242 Indirect Through ABG SRNE Limited See footnote
Common Stock 1,500,000 Indirect Through ABG Innovation-SO Limited See footnote
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Warrants $8.50 2019-05-31 432,432 432,432 Indirect
Common Stock Warrants $8.50 2019-05-31 432,432 432,432 Indirect
Common Stock Warrants $8.50 2019-06-07 540,540 540,540 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2019-05-31 432,432 432,432 Indirect
2019-05-31 432,432 432,432 Indirect
2019-06-07 540,540 540,540 Indirect
Footnotes
  1. The Reporting Persons are making this joint, single filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act 1934 as amended (the "Act").
  2. The Form 4 is filed by and on behalf of each of the following persons (each a "Reporting Person"): (i) ABG II-SO Limited ("ABG II-SO"), a British Virgin Islands limited company, (ii) Ally Bridge Group Capital Partners II, L.P., a Cayman Islands limited partnership, (iii) Ally Bridge LB Healthcare Master Fund Limited ("ABG LB"), a Cayman Islands limited company, (iv) Ally Bridge LB Management Limited, a Cayman Islands limited company, (v) ABG SRNE Limited ("ABG SRNE"), a British Virgin Islands limited company, (vi) Ally Bridge Group Innovation Capital Partners III, L.P., a Cayman Islands limited company, (vii) ABG Management Ltd., a Cayman Islands limited partnership, (viii) Mr. Fan Yu, a director of ABG LB and a shareholder and director of Ally Bridge LB Management Limited, and the sole shareholder and director of ABG Management Ltd., and (ix) Mr. Bin Li, a director and executive officer of ABG LB and a shareholder and director of Ally Bridge LB Management Limited.
  3. Each Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for the purpose of Section 16 of the Act or otherwise, the beneficial owner of any securities covered by this statement. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
  4. ABG II-SO directly owns 1,397,853 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Capital Partners II, L.P., as parent of ABG II-SO, (ii) ABG Management Ltd., as manager of Ally Bridge Group Capital Partners II, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
  5. ABG LB directly owns (i) 1,991,441 shares of common stock of the Issuer and (ii) warrants to purchase 432,432 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge LB Management Limited, as manager of ABG LB, (ii) Mr. Fan Yu, as a shareholder and director of Ally Bridge LB Management Limited, and (iii) Mr. Bin Li, as a shareholder and director of Ally Bridge LB Management Limited.
  6. ABG SRNE directly owns (i) 3,243,242 shares of common stock of the Issuer and (ii) warrants to purchase 972,972 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., as owner of the sole voting share of ABG SRNE, (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
  7. Ally Bridge Group Innovation Capital Partners III, L.P. is the owner of the sole voting share of ABG Innovation-SO Limited, a British Virgin Islands limited company, which directly owns 1,500,000 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
  8. The warrants are exercisable at any time on or after May 31, 2016.
  9. The warrants are exercisable at any time on or after June 7, 2016.